Metabolic monitoring in children 5 years of age and younger prescribed second-generation antipsychotic medications
| Autor: | Thomas Delate, Sheila R. Botts, Yardlee S. Kauffman |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Pediatrics
medicine.medical_specialty medicine.diagnostic_test business.industry medicine.medical_treatment Patient characteristics Retrospective cohort study Psychiatric Management of the Medically Complicated Patient 030227 psychiatry Health care delivery 03 medical and health sciences 0302 clinical medicine Neuropsychology and Physiological Psychology Blood pressure medicine Pharmacology (medical) Antipsychotic Medications 030212 general & internal medicine Neurology (clinical) General Pharmacology Toxicology and Pharmaceutics Adverse effect Antipsychotic business Lipid profile |
| Zdroj: | Mental Health Clinician. 7:1-6 |
| ISSN: | 2168-9709 |
| DOI: | 10.9740/mhc.2017.01.001 |
| Popis: | Introduction: The objective of this article was to identify the rates of patients ≤5 years of age who received recommended monitoring before and after second-generation antipsychotic (SGA) initiation and had an SGA metabolic adverse effect (MAE). Methods: This was a retrospective cohort analysis conducted at Kaiser Permanente Colorado, an integrated health care delivery system, between January 1, 2002, and June 30, 2011. Commercially insured patients ≤5 years of age newly initiated on an SGA were included. Patients were followed for up to 3 years. Metabolic monitoring included lipid profile, blood glucose, blood pressure, and weight measurements. Patient characteristics and outcomes were described using descriptive statistics. Results: A total of 40 patients were included. Overall, 2 (5.0%) patients received all recommended baseline monitoring, and no (0.0%) patients received all recommended follow-up monitoring. Weight monitoring was completed most frequently with rates of completion of 57.5%, 95.0%, 85.0%, and 76.5% at baseline and years 1, 2, and 3, respectively. At least 1 MAE was identified in 14/40 (35.0%), 5/28 (17.9%), and 2/17 (11.8%) patients during years 1, 2, and 3, respectively. The most frequent MAE identified was weight gain. Among patients identified with at least 1 MAE, 4/14 (28.6%), 2/5 (40.0%), and 2/2 (100%) received a behavioral intervention during years 1, 2, and 3, respectively. Discussion: Overall, baseline and follow-up metabolic monitoring were poor. Future studies should focus on examining barriers to monitoring in order to improve health care quality. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|